Intentar ORO - Gratis

THE HIDDEN RISKS OF AMERICA'S MOST POPULAR PRESCRIPTION PAINKILLER

Mint Mumbai

|

December 26, 2025

Gabapentin has soared in popularity as an alternative to opioids, but patients are finding it can cause harm

- Betsy McKay & Shalini Ramachandran

THE HIDDEN RISKS OF AMERICA'S MOST POPULAR PRESCRIPTION PAINKILLER

While the medical establishment has mostly maintained that gabapentin isn't habit-forming, some patients have reported debilitating adverse effects when they try to taper off it.

(istockphoto)

John Avery was just back from a guys’ golfing weekend and doing dead lifts at the gym in 2023 when he felt a pop in his lower back. A disc had slipped and was pressing on a nerve.

After months of rest, physical therapy and steroids, he was prescribed a drug called gabapentin by a pain management specialist who told Avery that it could help calm his nerve pain and that it was “nonaddictive,” Avery recalled. He took the medicine for a few days, then had surgery, and took it again for a little more than three weeks.

The 33-year-old former high-school physical education teacher in Newark, Ill., said he experienced a severe protracted withdrawal when he stopped, which led to neurological symptoms now that make his original back problem seem like “a paper cut” by comparison.

His symptoms include shaking and a burning sensation throughout his body, muscle spasms and a racing pulse. He can’t sleep for more than a half-hour at a time, and has lost so much weight that his wife said his calves are the size of her arms.

The change in his life, he said, is “beyond dramatic.”

Approved by the Food and Drug Administration decades ago for seizures and nerve pain from shingles, gabapentin is now the seventh-most widely prescribed drug in the U.S., according to the Iqvia Institute for Human Data Science. About 15.5 million people were prescribed gabapentin in 2024, according to an analysis by Centers for Disease Control and Prevention researchers.

Studies show that most of the prescriptions are written to treat conditions that it wasn't approved for—a practice that is legal and common, but means the FDA hasn't vetted its risks and benefits for those purposes.

MÁS HISTORIAS DE Mint Mumbai

Mint Mumbai

Airfares hit four-year low on weak traffic; IndiGo crisis dulls demand

India's average domestic airfares hit a four-year low in the December quarter, an unusual outcome for a seasonally strong period, as traffic slowed through 2025 and demand weakened on non-metro routes.

time to read

2 mins

January 10, 2026

Mint Mumbai

Jaipur's many sweet takes

A winter food walk through the bylanes of Pink City reveals rituals and craftsmanship

time to read

2 mins

January 10, 2026

Mint Mumbai

Mint Mumbai

Better than the real thing

STREAM OF STORIES

time to read

3 mins

January 10, 2026

Mint Mumbai

Mint Mumbai

XAI under fire for sexualized child photos on Grok

Elon Musk has repeatedly expanded the boundaries of permitted speech on his social-media platform X.

time to read

4 mins

January 10, 2026

Mint Mumbai

Mint Mumbai

Federal Bank unveils Fortuna Wave to appeal to all young, mobile-first clients

Federal Bank's new brand identity, anchored by a refreshed logo called Fortuna Wave, comes at a moment when legacy banks are being forced to rethink how they appear, speak and scale—not because the old has failed, but because the audience has shifted.

time to read

3 mins

January 10, 2026

Mint Mumbai

Dec gold ETFs log record ₹11,647 cr

India’s equity investors are flocking to gold exchange- traded funds as a hedge against stock market volatility amid global headwinds.

time to read

1 min

January 10, 2026

Mint Mumbai

Mint Mumbai

Blackstone checks into Taj Aravali, buys 50% for $110 mn

The asset manager eyes further expansion with significant stake in Bengaluru’s Ritz-Carlton

time to read

2 mins

January 10, 2026

Mint Mumbai

Mint Mumbai

Jewellery in India isn't just about the flex

A new book, 'Silver & Gold', is a reminder that jewellery has links to faith and culture in India

time to read

3 mins

January 10, 2026

Mint Mumbai

US trade fears rattle markets; Nifty below 26,000

Domestic equities were shaken by the ‘Trump factor’ throughout the week, leaving India the worst-performing major market globally as risk-off sentiment gripped investors.

time to read

1 mins

January 10, 2026

Mint Mumbai

December inflation likely up at 1.6%: Poll

India’s retail inflation has likely inched up to 1.6% in December from 0.7% in November, driven by shallower deflation in food items and the fading impact of a favourable base effect, according to a Mint poll of 5 economists.

time to read

1 min

January 10, 2026

Listen

Translate

Share

-
+

Change font size